Select a live conference near you from the list below.
|Southfield, MI||Regency Manor & Banquet Center||9/28/18
7:30 am-12:30 pm
|Manistee, MI||Little River Casino Resort||9/29/18
7:30 am-12:30 pm
|Montpelier, VT||Capitol Plaza||9/29/18
8:00 am-12:30 pm
|Stamford, CT||Tully Health Center||10/10/18
5:00 pm-8:45 pm
|Westfield, MA||Western Massachusetts Hospital||11/13/18
5:00 pm-8:30 pm
These activities were planned in collaboration with the Council of Medical Specialty Societies and the Federation of State Medical Boards.
Boston University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
These activities have been approved for AMA PRA credit.
AMA PRA Category 1 Credits™: Varies with meeting: See meeting agenda for details
Continuing Nursing Education Provider Unit, Boston University School of Medicine is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.
CNE Contact Hours: Varies with meeting: See meeting agenda for details
This program meets the criteria of the Massachusetts Board of Registration in Medicine for risk management and opioid education. Several states have similar requirements. Please check with your Board to determine if this activity will fulfill your state's specific requirements and be sure to check back here as we update and add approvals to these listed below.
This program meets the criteria of the Massachusetts Board of Registration in Medicine for risk management study.
This program meets the criteria of the Massachusetts Board of Registration in Medicine for opioid education.
This Live activity, SCOPE of Pain: Safe & Competent Opioid Prescribing Education, from 12/7/17-12/7/18, has been reviewed and is acceptable for up to 2.00 Prescribed credit(s) by the American Academy of Family Physicians. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 2 MOC points and patient safety MOC credit in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Through the American Board of Medical Specialties (ABMS) ongoing commitment to increase access to practice relevant Maintenance of Certification (MOC) Activities through the ABMS Continuing Certification Directory, SCOPE of Pain has met the requirements as an MOC Part II CME Activity (apply toward general CME requirement) and an MOC Part II Self-Assessment Activity for the following ABMS Member Boards:
MOC Part II CME Activity
MOC Part II Self-Assessment Activity
Note: If a Member Board has not deemed this activity for MOC approval as an accredited CME activity, this activity may count toward an ABMS Member Board's general CME requirement (only). Please refer directly to your Member Boards' MOC Part II Lifelong Learning and Self-Assessment Program Requirements.
Healthcare practitioners who prescribe ER/LA opioid analgesics to treat chronic pain are in a key position to balance the benefits and risks of Chronic Opioid Treatment (COT). The importance of education for HCPs cannot be overstated as, according to a 2011 report by the Institute of Medicine, the social and economic burden of pain nationwide is staggering. The IOM Report found that the annual health economic impact of pain represents a $560 to $635 billion burden to the U.S. The escalation of opioid prescribing and the corresponding increase in opioid misuse (including abuse, addiction, overdose, and diversion) have been well documented by both regulatory agencies and the lay press. According to SAMHSA's 2010 National Survey of Drug Use and Health report, among the U.S. population aged 12 or older, nonmedical use of prescription pain relievers was the second most prevalent type of illicit drug use after marijuana use. In addition, mortality rates from unintentional overdose of opioids are increasing dramatically. Despite these concerns, according to the National Institute on Drug Abuse, opioid pain medicines are safe and usually do not cause addiction when managed well medically and taken as prescribed. However, HCPs struggle with the need to assist their patients with adequate management of chronic pain while confronting the risks associated with opioid prescribing.
Physicians, nurse practitioners, registered nurses, nurses, physician assistants, dentists, and pharmacists
At the conclusion of these activities, participants will be better able to:
Boston University School of Medicine asks all individuals involved in the development and presentation of Continuing Medical Education (CME) activities to disclose all relationships with commercial interests. This information is disclosed to CME activity participants. Boston University School of Medicine has procedures to resolve apparent conflicts of interest. In addition, faculty members are asked to disclose when any discussion of unapproved use of pharmaceuticals and devices occurs.
This activity does include discussion of the off-label use of sublingual buprenorphine to treat pain. Sublingual buprenorphine has been FDA approved for addiction treatment but not pain treatment. This presentation does include discussion of the off-label use of clonidine and tizanidine to treat opioid withdrawal symptoms. Clonidine and tizanidine are not FDA approved for this use.
Daniel P. Alford, MD, MPH, FACP
Professor of Medicine
Boston University School of Medicine
Boston Medical Center
Faculty member has nothing to disclose with regards to commercial support.
Seddon Savage, MD
Adjunct Associate Professor of Anesthesiology
Geisel School of Medicine
Dartmouth Medical School
Dr. Savage has nothing to disclose with regards to commercial support.
Additional Original Content Development
Lynn Webster, MD, FACPM, FASAM, CRI-Lifetree
Dr. Webster is a consultant for Covidien Mallinckrodt, Medtronic, Nektar Therapeutics, and Salix Pharmaceuticals.
Online Program Moderator
Judie Yuill, Fill-in News Anchor and Host at WGBH Boston and Exclusive Female Voice at Parlance Corp
Ms. Judie Yuill has nothing to disclose with regard to commercial support.
Ms. Patti-Ann Collins, Lead Nurse Planner, Boston University School of Medicine CME Office
Ilana Hardesty, Program Operations Manager, Boston University School of Medicine CME Office
Ms. Colleen Labelle, CNE Course Advisor, Boston University School of Medicine CME Office
Stephen A. Wyatt, DO, and Jason Worcester, MD, independent reviewers
Planning Committee members have nothing to disclose with regard to commercial support.
Norman Kahn, MD, Executive Vice-President and CEO, Council of Medical Specialty Societies
Stancel Riley, MD, Lecturer on Surgery, Harvard Medical School and Research Associate, Department of Health Policy Management, Harvard School of Public Health
Lisa Robin, Chief Advocacy Officer for the Federation of State Medical Boards
Advisory Committee members have nothing to disclose with regard to commercial support.
THESE MATERIALS AND ALL OTHER MATERIALS PROVIDED IN CONJUNCTION WITH CONTINUING MEDICAL EDUCATION ACTIVITIES ARE INTENDED SOLELY FOR PURPOSES OF SUPPLEMENTING CONTINUING MEDICAL EDUCATION PROGRAMS FOR QUALIFIED HEALTH CARE PROFESSIONALS. ANYONE USING THE MATERIALS ASSUMES FULL RESPONSIBILITY AND ALL RISK FOR THEIR APPROPRIATE USE. TRUSTEES OF BOSTON UNIVERSITY MAKES NO WARRANTIES OR REPRESENTATIONS WHATSOEVER REGARDING THE ACCURACY, COMPLETENESS, CURRENTNESS, NONINFRINGEMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OF THE MATERIALS. IN NO EVENT WILL TRUSTEES OF BOSTON UNIVERSITY BE LIABLE TO ANYONE FOR ANY DECISION MADE OR ACTION TAKEN IN RELIANCE ON THE MATERIALS. IN NO EVENT SHOULD THE INFORMATION IN THE MATERIALS BE USED AS A SUBSTITUTE FOR PROFESSIONAL CARE.
This educational activity is supported by an independent educational grant from the Extended-Release/Long-Acting Opioid Analgesic REMS Program Companies. Please see http://ce.er-la-opioidrems.com/IwgCEUI/rems/pdf/List_of_RPC_Companies.pdf for a listing of REMS Program Companies. This activity is intended to be fully compliant with the Extended-Release/Long-Acting Opioid Analgesics REMS education requirements issued by the US Food & Drug Administration.
© 2018 Trustees of Boston University. Site by Signal.